Stockreport

ArQule Announces Release of American Society of Hematology Abstract Detailing Results of the Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractor...

ARQULE  (ARQL) 
Last arqule earnings: 10/30 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.arqule.com/investor-relations
PDF ARQ 531 demonstrates substantial anti-tumor activity in refractory CLL patients and manageable safety profileA total of 10 patients experienced partial responses (PRs) a [Read more]